Qiagen to Gain Array-Based Breast Cancer Test through Ipsogen Buy
June 21, 2011
Qiagen to Gain Array-Based Breast Cancer Test through Ipsogen Buy
Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.